Stock Ratings / Health Care / ENTA / dividends

PRLD (41) TTRX (31) BNTC (37) ARCT (31) ⌘ Pro Terminal →

Enanta Pharmaceuticals Inc. (ENTA) Dividend Safety Gauge & 10-Year DRIP Compounder

$11.15 -3.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.06

Enanta Pharmaceuticals Inc. (ENTA) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $324.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $11.06 (-0.81%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENTA)Realized 20D OHLCV Swing Band: ±11.7%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY ENTA SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+6/20 pts (24% of score)

20D Institutional Volume Accumulation (±11.7% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (24% of score)

FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 36.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.50-11.2% Next Q

Q2 (-2Q)

Grade E$11.10+4.9% Next Q

Q3 (-1Q)

Grade E$11.64-4.2% Next Q

Current

Grade E$11.15-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ENTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ENTA currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.53) and Max Pain ($11.71) forces dealer call-delta covering toward $18.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ENTA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENTA)

✓Walkthrough of ENTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ENTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.73%▼ DESCENDING CHANNEL

2026-10-30O $11.08H $11.15L $10.69C $11.15VOL 202.3K

RES: $14.47SUP: $10.56SMA50: $12.53SMA200: $13.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ENTA Butterfly Map → + Track ENTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ENTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ENTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ENTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENTA)

Health Care Rank #990 of 1016 ⚔️ PRLD vs ENTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ENTA vs. PRLD, TTRX, BNTC, ARCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Enanta Pharmaceuticals Inc. (ENTA) ranks #990 by composite RQD confidence (25/100, grade E) and #513 by equity capitalization ($324.7M). Within this direct 5-issuer industry benchmark cohort, ENTA leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. PRLD currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ENTA at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ENTA ACTIVE Enanta Pharmaceuticals Inc.	E	25/100	—	—	-35.0%	-3.46%	$324.7M	Benchmark Subject
PRLD Prelude Therapeutics Incorporated	D-	41/100	—	—	-35.0%	-0.97%	$327.2M	/prld-vs-enta →
TTRX Turn Therapeutics Inc.	E	31/100	—	—	-28.3%	-3.60%	$327.3M	/ttrx-vs-enta →
BNTC Benitec Biopharma Inc.	D-	37/100	—	—	-35.0%	+0.34%	$308.1M	/bntc-vs-enta →
ARCT Arcturus Therapeutics Holdings Inc.	E	31/100	—	—	-35.0%	+0.66%	$345.3M	/arct-vs-enta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001177648

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Enanta Pharmaceuticals Inc. (ENTA) reported GAAP revenue of $65.3M (-3.4% vs. FY2024 revenue of $67.6M , and -17.5% cumulative change since FY2023) , GAAP net income of -$81.9M, operating cash flow of -$19.3M, and free cash flow of -$32.2M (+66.7% YoY). On the balance sheet, ENTA closed FY2025 with $329.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$65.3M	-$81.9M	-$19.3M	-$32.2M	$329.5M	—
FY2024 (FY)	2024-09-30	$67.6M	-$116.0M	-$78.8M	-$96.7M	$348.6M	—
FY2023 (FY)	2023-09-30	$79.2M	-$133.8M	-$103.2M	-$103.2M	—	—

3. ENTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $11.15 (-3.46% 1D, market cap $324.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENTA ranks #990 in composite RQD confidence.

How does ENTA compare to PRLD and TTRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENTA carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRLD (Prelude Therapeutics Incorporated) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $327.2M) and TTRX (Turn Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -28.3%, cap $327.3M). Among the 5-stock peer group, ENTA leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENTA?

Per ENTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001177648), Enanta Pharmaceuticals Inc. generated $65.3M in revenue (-3.4% YoY), -$81.9M in net income, and -$32.2M in free cash flow against $329.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENTA trading relative to its 50-day, 200-day, and 52-week technical levels?

ENTA last traded at $11.15 (-3.46% on volume of 218,492 shares), positioning the stock -11.01% below its 50-day simple moving average ($12.53) and -15.47% below its 200-day simple moving average ($13.19). Across its 52-week range of $10.22 to $17.15, ENTA sits at the 13.4% percentile with a 14-day RSI of 36.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($9.85 to $12.45).

ENTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ENTA pay a dividend and is it safe?

Enanta Pharmaceuticals Inc. (ENTA) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ENTA RQD Cockpit ENTA 12M Forecast ENTA Earnings & Move ENTA Dividends & DRIP ENTA Insiders & 13F ENTA Whale Options ENTA Profit Sankey ENTA News & Why